31.69
+1.36
(4.48%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 29.86 - 31.78 |
| 52 week | 14.82 - 32.33 |
| Open | 30.31 |
| Vol / Avg. | 1.39M/1.61M |
| Mkt cap | 4.22B |
| P/E | - |
| Div/yield | - |
| EPS | -0.33 |
| Shares | 133.17M |
| Beta | 0.85 |
| Inst. own | 96% |
Events
May 23, 2013
Q4 2013 Alkermes plc Earnings Conference Call
- 8:00AM EDT -
May 23, 2013
Q4 2013 Alkermes plc Earnings Release
May 8, 2013
Alkermes plc at Bank of America Merrill Lynch Smid Cap Conference -
Mar 4, 2013
Alkermes plc at Cowen Health Care Conference -
Feb 26, 2013
Alkermes plc at RBC Capital Markets' Healthcare Conference -
Feb 25, 2013
Alkermes plc at Citi Global Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 11.96% | -29.15% |
| Operating margin | 18.59% | -22.64% |
| EBITD margin | - | 9.26% |
| Return on average assets | 4.69% | -12.04% |
| Return on average equity | 7.23% | -18.25% |
| Employees | 1,200 | - |
| Carbon Disclosure Rating | - | - |
Address
Connaught House 1 Burlington Road, Dublin 4
DUBLIN,
Ireland
+353-1-7728000 (Phone)
DUBLIN,
Ireland
+353-1-7728000 (Phone)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Alkermes plc., formerly Alkermes, Inc., is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. The Company develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. In September 2011, the Company started its corporate operations in Ireland. On September 16, 2011, the Company merged with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan Corporation, plc (Elan).
Officers and directors
| Richard F. Pops | Chairman, President, and CEO | |
| James M. (Jim) Frates | SVP, CFO, and Treasurer | |
| Gordon G. Pugh | SVP, COO, and Chief Risk Officer | |
| Richard F. Pops | Chairman of the Board, Chief Executive Officer | |
| Shane Cooke | President | |
| James M. Frates | Chief Financial Officer, Senior Vice President | |
| Gordon G. Pugh | Chief Operating Officer, Senior Vice President, Chief Risk Officer | |
| Kathryn L. Biberstein | Senior Vice President, Chief Compliance Officer, General Counsel, Secretary | |
| James L. Botkin | Senior Vice President - Operations | |
| Elliot W. Ehrich M.D. | Senior Vice President - Research and Development, Chief Medical Officer |